FDA Pulls 12 Peptides Off Its "Do Not Compound" List — What Changes, and What Doesn't

The three categories

The FDA's 503A interim bulks list sorts nominated peptide substances into three buckets. Category 1 means the agency has identified no significant safety risks and is exercising enforcement discretion — compounding is functionally permitted. Category 2 means significant safety risks have been identified — compounding is not permitted. Category 3 covers substances where the agency hasn't gathered enough information to decide.

For three years, popular research peptides have sat in Category 2 — placed there by a September 2023 action that the current administration has publicly characterized as having been improper. The April 15 announcement removes twelve of them from Category 2 by formally noting that their nominators withdrew the underlying nominations. The substances are no longer formally classified as "significant safety risks" — but they're not yet formally permitted, either.

What this means in practice

For the everyday research-peptide buyer and the encyclopedia user, three things are worth understanding clearly.

This is procedural, not approval. Removal from Category 2 means the prior enforcement basis is gone, but the peptides are not on Category 1. Compounding pharmacies cannot point to this notice and start dispensing immediately under the interim policy. The PCAC meetings on July 23–24, 2026 and again in early 2027 are where the substantive decision will be made about whether to add these to the 503A bulks list.

The supply-chain problem is real. Even if the FDA eventually moves these peptides to Category 1 or formally onto the bulks list, compounding pharmacies need pharmaceutical-grade active pharmaceutical ingredient (API) from FDA-registered facilities. Most popular research peptides today are sold only as research-grade material, which cannot lawfully be used in dispensed compounded products. A change in regulatory classification doesn't, by itself, create a compliant API supply.

Research-grade is unchanged. The legal status of research-use-only peptides — the kind sold by most US vendors with a "not for human consumption" label — is governed by separate frameworks (FDCA misbranding, controlled-substance scheduling where applicable, and state-level rules). The Category 2 update doesn't touch any of that.

Why this happened now

The political context is unusual. HHS Secretary Robert F. Kennedy Jr. publicly signaled in late February that the administration expected the FDA to expand lawful peptide compounding access. The April 15 notice and PCAC scheduling are the agency's first formal moves in that direction. Prior PCAC reviews under the previous administration had voted against inclusion of peptides on the bulks list in every case examined. Whether the upcoming committee — which has several vacancies the administration can fill — reaches a different conclusion is the next inflection point.

Related on Grey Peptides